Inflammatory mediators of cognitive impairment in bipolar disorder

Journal of Psychiatric Research

Volumn 56, Issue 1, 2014, Pages 18-27

  Bauer, Isabelle E ^a   Pascoe, Michaela C ^b   Wollenhaupt Aguiar, Bianca ^c   Kapczinski, Flavio ^a,c   Soares, Jair C ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Bipolar disorder; Cognitive functioning; Neuroinflammation; Neurotrophin; Oxidative stress

Indexed keywords

BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; NEUROTROPHIN;

BIPOLAR DISORDER; COGNITION; COGNITIVE DEFECT; DEPRESSION; DISEASE ASSOCIATION; EVALUATION STUDY; GENETIC POLYMORPHISM; HUMAN; HYPOTHESIS; MANIA; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NEUROTROPISM; OXIDATIVE STRESS; PRIORITY JOURNAL; PSYCHOSIS; QUALITY CONTROL; REVIEW; COMPLICATION; GENETICS; IMMUNOLOGY; IMMUNOMODULATION; PHYSIOLOGY;

BIPOLAR DISORDER; COGNITION DISORDERS; HUMANS; NEUROIMMUNOMODULATION;

EID: 84903774138     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2014.04.017     Document Type: Review

References (77)

1. Aas M., Haukvik U.K., Djurovic S., Bergmann Ø., Athanasiu L., Tesli M.S., et al. BDNF val66met modulates the association between childhood trauma, cognitive and brain abnormalities in psychoses. Prog Neuro-Psychopharmacol Biol Psychiatry 2013, 46:181-188.
2. Ancin I., Santos J.L., Teijeira C., Sanchez-Morla E.M., Bescos M.J., Argudo I., et al. Sustained attention as a potential endophenotype for bipolar disorder. Acta Psychiatr Scand 2010, 122(3):235-245.
3. Barbosa I.G., Huguet R.B., Sousa L.P., Abreu M.N.S., Rocha N.P., Bauer M.E., et al. Circulating levels of GDNF in bipolar disorder. Neurosci Lett 2011, 502(2):103-106.
4. Barbosa I.G., Rocha N.P., Huguet R.B., Ferreira R.A., Salgado J.V., Carvalho L.A., et al. Executive dysfunction in euthymic bipolar disorder patients and its association with plasma biomarkers. JAffect Disord 2012, 137(1):151.
5. Bearden C.E., Glahn D.C., Monkul E.S., Barrett J., Najt P., Villarreal V., et al. Patterns of memory impairment in bipolar disorder and unipolar major depression. Psychiatry Res 2006, 142(2):139-150.
6. Berk M., Conus P., Kapczinski F., Andreazza A.C., Yücel M., Wood S.J., et al. From neuroprogression to neuroprotection: implications for clinical care. Med J Aust 2010, 193(4 Suppl):S36-S40.
7. Berk M., Kapczinski F., Andreazza A., Dean O., Giorlando F., Maes M., et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 2011, 35(3):804-817.
8. Blank T., Prinz M. Microglia as modulators of cognition and neuropsychiatric disorders. Glia 2013, 61(1):62-70.
9. Boban M., Malojčić B., Mimica N., Vuković S., Zrilić I. The frontal assessment battery in the differential diagnosis of dementia. JGeriatr Psychiatry Neurol 2012, 25(4):201-207.
10. Bourne C., Aydemir Ö., Balanzá-Martínez V., Bora E., Brissos S., Cavanagh J., et al. Neuropsychological testing of cognitive impairment in euthymic bipolar disorder: an individual patient data meta-analysis. Acta Psychiatr Scand 2013, 128(3):149-162.
11. Brambilla P., Harenski K., Nicoletti M., Mallinger A.G., Frank E., Kupfer D.J., et al. Differential effects of age on brain gray matter in bipolar patients and healthy individuals. Neuropsychobiology 2001, 43(4):242-247.
12. Buckley P.F., Pillai A., Evans D., Stirewalt E., Mahadik S. Brain derived neurotropic factor in first-episode psychosis. Schizophr Res 2007, 91(1):1-5.
13. Capuron L., Dantzer R. Cytokines and depression: the need for a new paradigm. Brain Behav Immun 2003, 17(1):119-124.
14. Carey A.N., Fisher D.R., Joseph J.A., Shukitt-Hale B. The ability of walnut extract and fatty acids to protect against the deleterious effects of oxidative stress and inflammation in hippocampal cells. Nutr Neurosci 2013, 16(1):13-20.
15. Chou Y.-H., Wang S.-J., Lirng J.-F., Lin C.-L., Yang K.-C., Chen C.-K., et al. Impaired cognition in bipolar I disorder: the roles of the serotonin transporter and brain-derived neurotrophic factor. JAffect Disord 2012, 143:131-137.
16. Cochrane, Collaboration Cochrane reviewers' handbook. Version 4.2.1 2003.
17. Craddock N., O'donovan M., Owen M. The genetics of schizophrenia and bipolar disorder: dissecting psychosis. JMed Genet 2005, 42(3):193-204.
18. Cunha A., Frey B.N., Andreazza A.C., Goi J.D., Rosa A.R., Gonçalves C.A., et al. Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci Lett 2006, 398(3):215-219.
19. Czéh B., Lucassen P.J. What causes the hippocampal volume decrease in depression?. Eur Arch Psychiatry Clin Neurosci 2007, 257(5):250-260.
20. DeBattista C., Belanoff J. The use of mifepristone in the treatment of neuropsychiatric disorders. Trends Endocrinol Metab 2006, 17(3):117-121.
21. Dias V.V., Brissos S., Frey B.N., Andreazza A.C., Cardoso C., Kapczinski F. Cognitive function and serum levels of brain-derived neurotrophic factor in patients with bipolar disorder. Bipolar Disord 2009, 11(6):663-671.
22. Dickerson F., Stallings C., Origoni A., Vaughan C., Khushalani S., Yolken R. Elevated C-reactive protein and cognitive deficits in individuals with bipolar disorder. JAffect Disord 2013, 150(2):456-459.
23. Diwadkar V.A., Goradia D., Hosanagar A., Mermon D., Montrose D.M., Birmaher B., et al. Working memory and attention deficits in adolescent offspring of schizophrenia or bipolar patients: comparing vulnerability markers. Prog Neuro-Psychopharmacol Biol Psychiatry 2011, 35(5):1349-1354.
24. Doganavsargil-Baysal O., Cinemre B., Aksoy U.M., Akbas H., Metin O., Fettahoglu C., et al. Levels of TNF-α, soluble TNF receptors (sTNFR1, sTNFR2), and cognition in bipolar disorder. Hum Psychopharmacol Clin Exp 2013, 28(2):160-167.
25. Fernandes B.S., Gama C.S., Maria Ceresér K., Yatham L.N., Fries G.R., Colpo G., et al. Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. JPsychiatr Res 2011, 45(8):995-1004.
26. ® Axis I Disorders (SCID-I), Clinician Version, Administration Booklet 2012, American Psychiatric Pub.
27. Frey B.N., Valvassori S.S., Gomes K.M., Martins M.R., Dal-Pizzol F., Kapczinski F., et al. Increased oxidative stress in submitochondrial particles after chronic amphetamine exposure. Brain Res 2006, 1097(1):224-229.
28. Frey B.N., Valvassori S.S., Réus G.Z., Martins M.R., Petronilho F.C., Bardini K., et al. Changes in antioxidant defense enzymes after d-amphetamine exposure: implications as an animal model of mania. Neurochem Res 2006, 31(5):699-703.
29. Frey B.N., Zunta-Soares G.B., Caetano S.C., Nicoletti M.A., Hatch J.P., Brambilla P., et al. Illness duration and total brain gray matter in bipolar disorder: evidence for neurodegeneration?. Eur Neuropsychopharmacol 2008, 18(10):717-722.
30. Fries G.R., Pfaffenseller B., Stertz L., Paz A.V.C., Dargél A.A., Kunz M., et al. Staging and neuroprogression in bipolar disorder. Curr Psychiatry Rep 2012, 14(6):667-675.
31. Frodl T., Amico F. Is there an association between peripheral immune markers and structural/functional neuroimaging findings?. Prog Neuro-Psychopharmacol Biol Psychiatry 2013, 3(48):295-303.
32. Gama C.S., Kunz M., Magalhães P.V., Kapczinski F. Staging and neuroprogression in bipolar disorder: a systematic review of the literature. Rev Bras Psiquiatr 2013, 35(1):70-74.
33. Gigante A.D., Bond D.J., Lafer B., Lam R.W., Young L.T., Yatham L.N. Brain glutamate levels measured by magnetic resonance spectroscopy in patients with bipolar disorder: a meta-analysis. Bipolar Disord 2012, 14(5):478-487.
34. Gimeno D., Kivimaki M., Brunner E.J., Elovainio M., De Vogli R., Steptoe A., et al. Associations of C-reactive protein and interleukin-6 with cognitive symptoms of depression: 12-year follow-up of the Whitehall II study. Psychol Med 2009, 39(3):413.
35. Glahn D.C., Bearden C.E., Barguil M., Barrett J., Reichenberg A., Bowden C.L., et al. The neurocognitive signature of psychotic bipolar disorder. Biol Psychiatry 2007, 62(8):910-916.
36. Gluhm S., Goldstein J., Loc K., Colt A., Van Liew C., Corey-Bloom J. Cognitive performance on the mini-mental state examination and the Montreal cognitive assessment across the healthy adult lifespan. Cogn Behav Neurol 2013, 26(1):1-5.
37. Goldstein B.I., Collinger K.A., Lotrich F., Marsland A.L., Gill M.-K., Axelson D.A., et al. Preliminary findings regarding proinflammatory markers and brain-derived neurotrophic factor among adolescents with bipolar spectrum disorders. JChild Adolesc Psychopharmacol 2011, 21(5):479-484.
38. Grassi-Oliveira R., Brietzke E., Pezzi J.C., Lopes R.P., Teixeira A.L., Bauer M.E. Increased soluble tumor necrosis factor-α receptors in patients with major depressive disorder. Psychiatry Clin Neurosci 2009, 63(2):202-208.
39. Haas R.H., Parikh S., Falk M.J., Saneto R.P., Wolf N.I., Darin N., et al. Mitochondrial disease: a practical approach for primary care physicians. Pediatrics 2007, 120(6):1326-1333.
40. Huang E.J., Reichardt L.F. Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci 2001, 24:677.
41. Ibrahim A.K., Kelly S.J., Adams C.E., Glazebrook C. Asystematic review of studies of depression prevalence in university students. JPsychiatr Res 2012, 47(3):391-400.
42. Ichim G., Tauszig-Delamasure S., Mehlen P. Neurotrophins and cell death. Exp Cell Res 2012, 318(11):1221-1228.
43. Jiang L., Shi Y., Wang L., Yang Z. The influence of orally administered docosahexaenoic acid on cognitive ability in aged mice. JNutr Biochem 2009, 20(9):735-741.
44. Kapczinski F., Vieta E., Andreazza A.C., Frey B.N., Gomes F.A., Tramontina J., et al. Allostatic load in bipolar disorder: implications for pathophysiology and treatment. Neurosci Biobehav Rev 2008, 32(4):675-692.
45. Kapczinski F., Dias V.V., Kauer-Sant'Anna M., Frey B.N., Grassi-Oliveira R., Colom F., et al. Clinical implications of a staging model for bipolar disorders. Expert Rev Neurother 2009, 9(7):957-966.
46. Kapczinski F., Dal-Pizzol F., Teixeira A.L., Magalhaes P.V., Kauer-Sant'Anna M., Klamt F., et al. Peripheral biomarkers and illness activity in bipolar disorder. JPsychiatr Res 2011, 45(2):156-161.
47. Katan M., Deslypere J., Van Birgelen A., Penders M., Zegwaard M. Kinetics of the incorporation of dietary fatty acids into serum cholesteryl esters, erythrocyte membranes, and adipose tissue: an 18-month controlled study. JLipid Res 1997, 38(10):2012-2022.
48. Kauer-Sant'Anna M., Kapczinski F., Andreazza A.C., Bond D.J., Lam R.W., Young L.T., et al. Brain-derived neurotrophic factor and inflammatory markers in patients with early-vs. late-stage bipolar disorder. Int J Neuropsychopharmacol 2009, 12(04):447-458.
49. King D.A., Caine E.D. Cognitive impairment and major depression: beyond the pseudodementia syndrome. Neuropsychological assessment of neuropsychiatric disorders 1996, Oxford University Press, New York. I. Grant, K.M. Adams (Eds.).
50. Kunz M., Ceresér K.M., Goi P.D., Fries G.R., Teixeira A.L., Fernandes B.S., et al. Serum levels of IL-6, IL-10 and TNF-α in patients with bipolar disorder and schizophrenia: differences in pro-and anti-inflammatory balance. Rev Bras Psiquiatr 2011, 33(3):268-274.
51. Mackin P., Gallagher P., Watson S., Young A.H., Ferrier I.N. Changes in brain-derived neurotrophic factor following treatment with mifepristone in bipolar disorder and schizophrenia. Aust N Z J Psychiatry 2007, 41(4):321-326.
52. Malhi G.S., Ivanovski B., Hadzi-Pavlovic D., Mitchell P.B., Vieta E., Sachdev P. Neuropsychological deficits and functional impairment in bipolar depression, hypomania and euthymia. Bipolar Disord 2007, 9(1-2):114-125.
53. Mattson M.P. Apoptosis in neurodegenerative disorders. Nat Rev Mol Cell Biol 2000, 1(2):120-130.
54. Mattson M.P., Keller J.N., Begley J.G. Evidence for synaptic apoptosis. Exp Neurol 1998, 153(1):35-48.
55. Miller B.J., Buckley P., Seabolt W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 2011, 70(7):663-671.
56. Minagar A., Alexander J.S. Inflammatory disorders of the nervous system: pathogenesis, immunology, and clinical management 2005, Springer.
57. Minuzzi L., AntÔnio G., Fonseca Moreira J.C., Frey B.N. Mitochondrial dysfunction in bipolar disorder: lessons from brain imaging and molecular markers. Rev Colomb Psiquiatr 2011, 40(Suppl.1):166-182.
58. Moher D.L.A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009, 6(6):e1000097. The PRISMA Group.
59. Murphy M.P. Mitochondrial dysfunction indirectly elevates ROS production by the endoplasmic reticulum. Cell Metab 2013, 18(2):145-146.
60. Myint A.M., Schwarz M.J., Steinbusch H.W., Leonard B.E. Neuropsychiatric disorders related to interferon and interleukins treatment. Metab Brain Dis 2009, 24(1):55-68.
61. Najt P., Perez J., Sanches M., Peluso M., Glahn D., Soares J.C. Impulsivity and bipolar disorder. Eur Neuropsychopharmacol 2007, 17(5):313-320.
62. Pace T.W.W., Hu F., Miller A.H. Cytokine-effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. Brain Behav Immun 2007, 21(1):9-19.
63. Pattanayak R.D., Sagar R., Mehta M. Neuropsychological performance in euthymic Indian patients with bipolar disorder type I: correlation between quality of life and global functioning. Psychiatry Clin Neurosci 2012, 66(7):553-563.
64. Pfaffenseller B., Gama C.S., Kapczinski F., Duarte J.A., Kunz M. Anatomical faces of neuroprogression in bipolar disorder. Neuropsychiatry 2012, 2(4):279-280.
65. Quraishi S., Frangou S. Neuropsychology of bipolar disorder: a review. JAffect Disord 2002, 72(3):209.
66. Robinson L.J., Thompson J.M., Gallagher P., Goswami U., Young A.H., Ferrier I.N., et al. Ameta-analysis of cognitive deficits in euthymic patients with bipolar disorder. JAffect Disord 2006, 93(1-3):105-115.
67. Rybakowski J.K., Suwalska A. Excellent lithium responders have normal cognitive functions and plasma BDNF levels. Int J Neuropsychopharmacol 2010, 13(05):617-622.
68. Rybakowski J.K., Borkowska A., Czerski P.M., Skibińska M., Hauser J. Polymorphism of the brain-derived neurotrophic factor gene and performance on a cognitive prefrontal test in bipolar patients. Bipolar Disord 2003, 5(6):468-472.
69. Rybakowski J.K., Borkowska A., Skibinska M., Szczepankiewicz A., Kapelski P., Leszczynska-Rodziewicz A., et al. Prefrontal cognition in schizophrenia and bipolar illness in relation to Val66Met polymorphism of the brain-derived neurotrophic factor gene. Psychiatry Clin Neurosci 2006, 60(1):70-76.
70. Sheehan D.V., Lecrubier Y., Harnett Sheehan K., Janavs J., Weiller E., Keskiner A., et al. The validity of the Mini International Neuropsychiatric Interview (MINI) according to the SCID-P and its reliability. Eur Psychiatry 1997, 12(5):232-241.
71. Slifka M.K., Antia R., Whitmire J.K., Ahmed R. Humoral immunity due to long-lived plasma cells. Immunity 1998, 8(3):363-372.
72. Strakowski S. The bipolar brain: integrating neuroimaging and genetics 2012, Oxford University Press.
73. Strakowski S.M., Adler C.M., Almeida J., Altshuler L.L., Blumberg H.P., Chang K.D., et al. The functional neuroanatomy of bipolar disorder: a consensus model. Bipolar Disord 2012, 14(4):313-325.
74. Tramontina J.F., Yates D., Magalhães P.V.d.S., Trentini C., Sant'Anna M.K., Fries G.R., et al. Brain-derived neurotrophic factor gene val66met polymorphism and executive functioning in patients with bipolar disorder. Rev Bras Psiquiatr 2009, 31(2):136-140.
75. Turner E.H. Publication bias, with a focus on psychiatry: causes and solutions. CNS Drugs 2013, 27(6):457-468.
76. Watson S., Gallagher P., Porter R.J., Smith M.S., Herron L.J., Bulmer S., et al. Arandomized trial to examine the effect of mifepristone on neuropsychological performance and mood in patients with bipolar depression. Biol Psychiatry 2012, 72(11):943-949.
77. Young A.H., Gallagher P., Watson S., Del-Estal D., Owen B.M., Ferrier I.N. Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology 2004, 8(29):1538-1545.